Table 4 Association of Polymorphisms cMyc-N11S and p27-V109G with Breast Cancer Survival
From: Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis
| Â | Distant Recurrence Free Survival | Overall Survival | ||||
|---|---|---|---|---|---|---|
| Â | NR/N | unadjusted HR (95% CI) | adjusted1 HR (95% CI) | ND/N | unadjusted HR (95% CI) | adjusted1 HR (95% CI) |
cMyc-N11S (A>G) | Â | Â | Â | Â | Â | Â |
AA | 108/861 | 1.00 | 1.00 | 77/876 | 1.00 | 1.00 |
AG/GG | 5/74 | 0.54 (0.22–1.32) | 0.50 (0.20–1.23) | 5/76 | 0.77 (0.31–1.91) | 0.63 (0.23–1.75) |
p-value | Â | 0.17 | 0.13 | Â | 0.58 | 0.38 |
p27-V109G (T>G) | Â | Â | Â | Â | Â | Â |
TT | 67/570 | 1.00 | 1.00 | 47/579 | 1.00 | 1.00 |
TG/GG | 46/367 | 1.05 (0.72–1.53) | 1.00 (0.68–1.48) | 35/375 | 1.11 (0.72–1.72) | 0.97 (0.61–1.55) |
p-value | Â | 0.79 | 0.99 | Â | 0.65 | 0.90 |
Combined | Â | Â | Â | Â | Â | Â |
cMyc AA + p27 TT | 63/522 | 1.00 | 1.00 | 43/529 | 1.00 | 1.00 |
cMyc AA + p27 TG/GG | 45/330 | 3.34 (0.46–24.1) | 3.83 (0.53–27.7) | 34/338 | 2.23 (0.31–16.2) | 2.57 (0.35–18.8) |
cMyc AG/GG + p27 TT | 4/45 | 3.70 (0.51–26.8) | 3.71 (0.51–27.0) | 4/47 | 2.64 (0.36–19.3) | 2.45 (0.33–18.0) |
cMyc AG/GG + p27 TG/GG | 1/28 | 2.40 (0.27–21.5) | 2.37 (0.27–21.3) | 1/28 | 2.37 (0.26–21.2) | 2.35 (0.26–21.1) |
p-value | Â | 0.51 | 0.47 | Â | 0.73 | 0.83 |